Pharma R&D Outsourcing Market

Key Highlights of the Report

The global pharma R&D outsourcing market is divided into four sections: product type, development stage, firm size, therapy area, and region. Small molecules pharma R&D outsourcing is the most prevalent, with clinical and non-clinical development being the two key stages of development. The large companies category is dominating market demand, cardiovascular diseases are significant, driving growth in the pharmaceutical R&D outsourcing industry, with North America leading market growth.

The global pharma R&D outsourcing industry is driven by various factors, including increased usage of cloud computing and related software platforms in research and development, as well as Al’s appearance in drug discovery and development. Other restrictions include worries about intellectual property, as well as the high cost and low success rate of pharmaceutical research and development. However, the industry faces significant challenges related to intellectual property protection, quality control, and regulatory compliance.

Nonetheless, the worldwide pharmaceutical R&D outsourcing market offers considerable potential opportunities, including increased venture capitalist investments in the Life Sciences/Blotch Industry, as well as access to specialist knowledge. Furthermore, artificial intelligence and machine learning are two examples of technical advances that are expected to gain traction in the market.

Market Overview

The global pharma R&D outsourcing market has grown steadily in recent years and is predicted to increase at a CAGR of 9.56% between 2023 and 2030. In 2022, the market was worth USD 72.1 billion, and it is predicted to grow to USD 136.6 billion by 2030.

What Are the Primary Forces Driving the Global Pharma R&D Outsourcing Market?

Several factors are driving the worldwide pharma R&D outsourcing industry, including increased usage of cloud computing and related software platforms in research and development, as well as Al’s appearance in drug discovery and development.

What Are the Global Pharma R&D Outsourcing Market’s Major Challenges?

A variety of problems, such as quality control, regulatory compliance, and intellectual property protection also hampers the global pharmaceutical R&D outsourcing market.

What Are the Opportunities for Growth in the Global Pharma R&D Outsourcing Market?

Venture capitalist investments in the Life Sciences/Blotch Industry are expanding, as is access to specialist knowledge in the worldwide pharmaceutical R&D outsourcing sector.

Executive Summary

Overview of the Global Pharma R&D Outsourcing Market

The pharmaceutical R&D outsourcing market refers to the practice of pharmaceutical corporations outsourcing R&D activities to third-party service providers. This might involve a wide spectrum of drug discovery, preclinical and clinical development, regulatory affairs, and manufacturing activities. Factors driving the market include:

• Rising R&D expenses.
• A growing demand for specialized expertise.
• An increase in the number of small and mid-sized pharmaceutical enterprises.

However, worries about data privacy and security, a lack of control over outsourced tasks, and quality and regulatory compliance challenges are projected to limit market expansion.

Market Definition

The market for pharmaceutical R&D outsourcing describes the practice of pharmaceutical corporations contracting out their R&D work to outside service organizations. The activities involved in drug research, preclinical and clinical development, regulatory affairs, and manufacturing might range widely. In addition to other specialist service providers, the market includes a wide range of contract development and manufacturing organizations (CDMOs), contract research organizations (CROs), and other service providers.

Market Insights

• Global demand for pharmaceutical R&D outsourcing was worth USD 72.1 billion in 2022 and is predicted to reach USD 136.6 billion in 2030, expanding at a CAGR of 9.56% between 2023 and 2030.
• The small molecules sector accounted for a sizable share of the pharma R&D outsourcing industry, while the biologics segment will likely exhibit the fastest CAGR during the forecast period
• The clinical category had a significant proportion of roughly 64.13%, while the non-clinical segment is one of the fastest expanding segments in the pharmaceutical R&D outsourcing market
• In 2022, the small and mid-sized companies segment held a significant proportion of roughly 57.54%, while The Large companies segment is leading the market demand.
• The oncology section held a significant proportion of roughly 30.71%.
• North America is the most important market for pharmaceutical R&D outsourcing, accounting for a sizable portion of the global market, while the Asia-Pacific region is expected to have the greatest CAGR in the pharmaceutical R&D outsourcing market.
• Increased use of cloud computing and related software platforms in research and development, as well as Al’s appearance in drug discovery and development, are the major drivers of the market.
• At the same time, Concerns over intellectual property, as well as the high cost and low success rate of pharmaceutical research and development, are the main restraints.
• Venture capitalist investments in the Life Sciences/Blotch Industry are increasing, as is access to specialized knowledge are the major opportunities in the market.

Segmentation by Product Type

• The small molecules sector accounted for a sizable share of the pharma R&D outsourcing industry.
• The biologics segment will likely exhibit the fastest CAGR during the forecast period.

Segmentation by Stage of Development

• In 2022, the clinical category had a significant proportion of roughly 64.13%.
• The non-clinical segment is one of the fastest-expanding segments in the pharmaceutical R&D outsourcing market.

Segmentation by Company Size

• In 2022, the small and mid-sized companies segment held a significant proportion of roughly 57.54%.
• The Large companies segment is leading the market demand.

Segmentation by Therapy Area

• In 2022, the oncology section held a significant proportion of roughly 30.71%.
• The infectious diseases segment also contributes significantly to the pharmaceutical R&D outsourcing market.
• The market for new and innovative medicines for cardiovascular diseases is considerable, which is driving growth in the pharmaceutical R&D outsourcing market.

Segmentation by Region

• North America is the most important market for pharmaceutical R&D outsourcing, accounting for a sizable portion of the global market.
• The Asia-Pacific region is expected to have the greatest CAGR in the pharmaceutical R&D outsourcing market during the projected period.
• The rest of the World, including Latin America, The Middle East, and Africa, contributes the remainder to the demand for pharma R&D outsourcing.

The growing demand for pharma R&D outsourcing can be traced to the increased usage of cloud computing and related software platforms in research and development, as well as Al’s appearance in drug discovery and development. However, the market is constrained by intellectual property concerns and the high cost and low success rate of pharmaceutical research and development.

North America is the largest market for pharmaceutical R&D outsourcing, accounting for a sizable portion of the global market. The United States is the largest market in North America, owing to the presence of several of the world’s major pharmaceutical corporations, as well as a huge number of specialized service providers. Europe is the second-largest market for pharmaceutical R&D outsourcing, with the UK and Germany being important players.

The Asia-Pacific area is also a big market, with key outsourcing destinations such as India and China. There are also considerable disparities in the level of outsourcing activity within these regions, with certain countries and regions having a more developed outsourcing ecosystem than others. India, for example, has a significant number of CROs and CDMOs as well as a highly skilled staff, making it a favorite outsourcing destination for pharmaceutical corporations. Similarly, the UK has a well-developed regulatory environment and a highly skilled population, which has contributed to the region’s outsourcing activity.

Overall, the expanding usage of cloud computing and related software platforms in research and development, as well as Al’s appearance in drug discovery and development, can be attributable to the increased demand for pharma R&D outsourcing.

Increased Use of Cloud Computing and Related Software Platforms in R&D

Even though many worldwide firms are utilizing cloud infrastructure to allow employees to work from home, many may still require optimization of their cloud and data strategies to aid in innovation, research, and development. The cloud can immediately build up infrastructure, grow or shrink as needed, and secure physical data centers and virtual networks, making it an excellent way to assist R&D. Furthermore, businesses can develop secure digital apps and platforms more quickly. Finally, the cloud provides the ability to store and combine data across a secure network. This feature allows for interoperable data and cooperation, collaboration, and co-creation among organizations. The cloud makes data possible, and projects to modernize data are closely related to the cloud.

By 2025, the amount of data generated by human genome sequencing is expected to reach 40 exabytes, and scientists will have spent up to 30%–40% of their time looking for, combining, and cleaning data. The cloud could be a game changer in terms of bringing drugs to market faster and at a lower cost. It has already beaten the world record for analyzing elastic genetic data. According to various studies, combining infrastructure and resources for master protocols can reduce research cycle time by 12-17% while reducing overall expenses by 11-14%, accelerating market growth.

Al’s Appearance in Drug Discovery and Development

Al has a big impact on healthcare, especially in the pharmaceutical business, where it’s employed for drug research and development, clinical trials, and pharmaceutical productivity. The search for new drugs takes a long time. The life cycle of a new medication entails a series of intricate tasks that demand time and development from the lab to the pharmacy. With Al’s assistance, these complex occurrences will occur less frequently, and pharmaceutical companies will be able to achieve their goal of developing a medicine more swiftly.

Pharmaceutical corporations have made numerous advances but have yet to see a return on their R&D efforts. The average investment in research and development for successful drug development is USD 2.6 billion. This cost includes millions of compounds’ recurrent success or failure in the R&D process to acquire approval. To deliver high-quality findings fast, several pharmaceutical businesses use cutting-edge technology such as Al and machine learning. These initiatives can generate a tremendous amount of data, and Al can sort the correct experiment information. Al has been used more frequently in advanced studies in recent years, propelling the market’s growth.

Pharmaceutical R&D is expensive and has a low success rate

The pharmaceutical sector spent 83 billion USD on research and development in 2019. These expenses were incurred for a number of activities, including the discovery and testing of novel medications, the development of incremental advances such as product modifications, and clinical testing for safety monitoring or marketing. The percentage of revenue spent on R&D by pharmaceutical businesses is also increasing. Developing novel medications is costly and uncertain, and many prospective drugs never make it to market.

 Only 12% of medications that have undergone thorough preclinical testing and clinical trials are approved by the FDA. The development process might also take more than 10 years, during which time the corporation receives no financial incentive for investing in the drug’s development, impeding market expansion.

Concerns About Intellectual Property

Pharmaceutical research and development (R&D) outsourcing has grown in popularity in recent years as it helps pharmaceutical corporations to decrease expenses and hasten the medication development process. However, one key impediment to the pharmaceutical R&D outsourcing business is the issue of intellectual property (IP) concerns.

When pharmaceutical companies outsource R&D activities to third-party service providers, they may be obliged to reveal sensitive information about medication development, such as trade secrets, intellectual information, and confidential data. This can pose considerable dangers in terms of intellectual property theft, infringement, and misappropriation, with serious ramifications for the pharmaceutical company and its stakeholders.

To overcome this issue, pharmaceutical companies must be proactive in controlling their intellectual property risks, such as creating appropriate contracts, confidentiality agreements, and security standards with their outsourcing partners. They must also verify that their outsourcing partners have the required experience, resources, and infrastructure to secure their intellectual property while maintaining the highest data security and confidentiality standards. By following these procedures, pharmaceutical companies can reduce the risks connected with intellectual property problems while continuing to reap the benefits of R&D outsourcing.

Venture Capitalist Investments in the Life Sciences/Blotch Industry are on the Rise

Big pharma’s attention and corporate investment are dominated by experimental anti-cancer medications, including lead generation platform technology, metabolism, ophthalmology, cardiology, central nervous system (CNS), dermatological, gastrointestinal (G. I.), and inflammation. Novartis, One, Amgen, Astellas, Pfizer, S.R. and J&J Development Corp. are among the industry’s biggest corporate venture investors. More than half of these new investments, according to SVB, were in preclinical or Phase I enterprises.

The strong venture capital sector practiced by private investors in new biopharma businesses is an important component of the US biopharma innovation ecosystem. Venture capital investment in biotechnology firms has reached new heights in recent years. This investment comprises huge sums of money given to biotechnology startups by existing biopharma businesses through their corporate venture capital (CVC) divisions. A corporation participates in CVC activity, a subset of venture capital investment when it invests in an affiliate. Typically, investment is given to a promising startup in the company’s field. Record-breaking investments in the biopharma industry have created a plethora of new prospects in global healthcare.

Access to Specialized Knowledge

Pharmaceutical research and development is a complex and highly specialized industry that necessitates a diverse set of skills, including scientific, technological, regulatory, and legal understanding. Pharmaceutical businesses can get access to a bigger pool of specialized expertise by outsourcing R&D efforts to third-party service providers. This can involve, among other things, expertise in specialized therapeutic areas, medication delivery technology, clinical trial design, and regulatory compliance.

Access to specialist expertise can assist pharmaceutical businesses to accelerate drug development, decrease costs, and improve product quality. It might also assist them in remaining competitive in a continuously changing market by keeping up with the most recent scientific and technological advancements.

Pharmaceutical businesses must carefully select their outsourcing partners based on their expertise, experience, and track record in order to capitalize on this potential. They must also guarantee that their outsourcing partners understand and can work together to achieve their business objectives, priorities, and values. Pharmaceutical firms can achieve a competitive advantage in the market by using the benefits of specialized expertise.

Competitive Landscape

Key Players

The global pharma R&D outsourcing market is highly competitive, with the presence of several key players. Some of the major players in the market and their market share are as follows:

• Charles River Laboratories
• ICON
• IQVIA
• Labcorp Drug Development
• Medpace
• Parexel International Corporation
• Syneos Health
• Thermo Fisher Scientific
• Wuxi AppTec
• Lonza
• Boehringer Ingelheim
• Samsung Biologics
• AbbVie
• Advanced Clinical
• BioAnalytix
• Asymchem
• Alcami
• Bavarian Nordic
• Catalent
• Curia Global
• ChemPartner
• CMED
• Criterium
• Cromos Pharma
• Evotec
• Jubilant HollisterStier
• KBI Biopharma
• KCR S.A.
• Kemwell Biopharma
• Mesned Pharma Consult Center
• Midas Pharma
• Medelis
• Merck KGaA
• OCT Clinical
• Pharmaceutics International
• ProTrials Research
• PROMETRIKA
• QPS
• Singota Solutions
• Sofpromed
• Sanofi
• Taros chemicals
• Veristat
• Worldwide Clinical Trials
• WuXi Biologics
• Wacker Biotech B.V
• Others

These companies focus on product innovation, expanding their distribution channels, and mergers and acquisitions to stay ahead in the market. The major players in the global pharma R&D outsourcing market are constantly striving to stay ahead by introducing new products and innovations.

In order to launch the nation’s first Prime Site in November 2022, IQVIA Holdings Inc. signed a long-term cooperation with Clalit, the leading supplier of healthcare services in Israel. The collaboration brings together the strengths of IQVIA and Clalit in data, genomics, real-world research, and clinical trial delivery.

Lonza unveiled a groundbreaking new capsule solution for enteric (intestinal) medication administration in November 2022. The contents of the Capsugel EnprotectTM capsule are only released in the intestine and do not disintegrate during stomach transit. Because they do not need to be coated or sealed in any other manner, Capsugel EnprotectTM capsules make it much easier to manufacture drug products.

Summary of Key Findings

• Increased use of cloud computing and related software platforms in research and development, as well as Al’s appearance in drug discovery and development, driving market growth
• Market segmented by Product type, stage of development, and company size. Therapy area and region.
• The large companies segment is leading the market demand.
• The biologics segment will likely exhibit the fastest CAGR during the forecast period.
• North America is leading market growth; the market is highly competitive with key players including Advanced Clinical, BioAnalytix, Asymchem and Alcam.

Future Outlook

• It is projected that technical advancements like artificial intelligence and machine learning would gain industry traction.
• It is projected that there will be more competition in the industry as new service providers enter the space and existing ones expand their product portfolios.
• Political and regulatory developments, such as modifications to the rules governing drug pricing, may have an effect on the market in the future.
• The need for pharmaceutical R&D outsourcing services has surged as a result of the COVID-19 pandemic, and this trend is anticipated to remain for the foreseeable future.

Segmentation

• • By Product Type
  • Small Molecules
  • Biologics
• By Stage of Development
  • Clinical
  • Non-Clinical
• By Company Size
  • Small & Mid-Sized Companies
  • Large Companies
• By Therapy Area
  • Oncology
  • Cardiovascular Diseases
  • Infectious Diseases
  • Musculoskeletal Disorders
  • Central Nervous System Disorders
  • Gastrointestinal Disorders
  • Other Therapy Areas
• By Region
  • North America

• • • The US.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • The U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of the Middle East and Africa

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – DataModelling
1.3.2.1. Company Share Analysis Model
1.3.2.2. Revenue Based Modelling
1.3.3. Phase III – Primary Research
1.3.4. Research Limitations
1.3.5. Assumptions
1.4. Market Introduction
1.5. Market Research Scope

2. Executive Summary
2.1. Market Snapshot: Global Pharma R&D Outsourcing Market
2.2. Global Pharma R&D Outsourcing Market, By Product Type
2.3. Global Pharma R&D Outsourcing Market, By Stage of development
2.4. Global Pharma R&D Outsourcing Market, By Company Size
2.5. Global Pharma R&D Outsourcing Market, By Therapy Area
2.6. Global Pharma R&D Outsourcing Market, By Region

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Pharma R&D Outsourcing Market Value, 2017-2030, (US$ Bn)
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.2. Market Restraints
3.2.3. Market Opportunities
3.2.4. Major Industry Challenges
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. Product Type
3.5.2. Stage of development
3.5.3. Company Size
3.5.4. Therapy Area
3.5.5. Geography

4. Premium Insights
4.1. STAR (Situation, Task, Action, Results) Analysis
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers/Consumers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitute Types
4.2.5. Intensity of Competitive Rivalry
4.3. Key Market Trends
4.3.1. Demand Side Trends
4.3.2. Supply Side Trends
4.4. Value Chain Analysis
4.5. Product Type Analysis
4.6. Analysis and Recommendations
4.7. Marketing Strategy Analysis
4.7.1. Direct Marketing
4.7.2. Indirect Marketing
4.7.3. Marketing Channel Development Trend

5. Market Positioning of Key Players, 2022
5.1. Company market share of key players, 2022
5.2. Competitive Benchmarking
5.3. Market Positioning of Key Vendors
5.4. Geographical Presence Analysis
5.5. Major Strategies Adopted by Key Players
5.5.1. Key Strategies Analysis
5.5.2. Mergers and Acquisitions
5.5.3. Partnerships
5.5.4. Product Type Launch
5.5.5. Geographical Expansion
5.5.6. Gastrointestinal Disorders

6. Economic Impact Analysis
6.1. Recession Impact
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Latin America
6.1.5. Middle East and Africa
6.2. Ukraine-Russia War Impact
6.2.1. North America
6.2.2. Europe
6.2.3. Asia Pacific
6.2.4. Latin America
6.2.5. Middle East and Africa
6.3. COVID-19 Impact Analysis
6.3.1. North America
6.3.2. Europe
6.3.3. Asia Pacific
6.3.4. Latin America
6.3.5. Middle East and Africa

7. Global Pharma R&D Outsourcing Market, By Product Type
7.1. Global Pharma R&D Outsourcing Market Overview, By Product Type
7.1.1. Global Pharma R&D Outsourcing Market Revenue Share, By Product Type, 2022 Vs 2030 (in %)
7.2. Small Molecules
7.2.1. Global Pharma R&D Outsourcing Market, By Region, 2017-2030 (US$ Bn)
7.3. Biologics
7.3.1. Global Pharma R&D Outsourcing Market, By Region, 2017-2030 (US$ Bn)

8. Global Pharma R&D Outsourcing Market, By Stage of development
8.1. Global Pharma R&D Outsourcing Market Overview, By Stage of development
8.1.1. Global Pharma R&D Outsourcing Market, By Stage of development, 2022 vs. 2030 (in%)
8.2. Clinical
8.2.1. Global Pharma R&D Outsourcing Market, By Region, 2017-2030 (US$ Bn)
8.3. Non-Clinical
8.3.1. Global Pharma R&D Outsourcing Market, By Region, 2017-2030 (US$ Bn)

9. Global Pharma R&D Outsourcing Market, By Company Size, 2017-2030(US$ Bn)
9.1. Global Pharma R&D Outsourcing Market Overview, By Company Size
9.1.1. Global Pharma R&D Outsourcing Market, By Company Size, 2022 vs 2030 (in%)
9.2. Small & Mid-Sized Companies
9.2.1. Global Pharma R&D Outsourcing Market, By Region, 2017-2030 (US$ Bn)
9.3. Large Companies
9.3.1. Global Pharma R&D Outsourcing Market, By Region, 2017-2030 (US$ Bn)

10. Global Pharma R&D Outsourcing Market, By Therapy Area, 2017-2030(US$ Bn)
10.1 Global Pharma R&D Outsourcing Market Overview, By Therapy Area
10.1.1. Global Pharma R&D Outsourcing Market, By Therapy Area, 2022 vs 2030 (in %)
10.2. Oncology
10.2.1. Global Pharma R&D Outsourcing Market, By Region, 2017-2030 (US$ Bn)
10.3. Cardiovascular Diseases
10.3.1. Global Pharma R&D Outsourcing Market, By Region, 2017-2030 (US$ Bn)
10.4. Infectious Diseases
10.4.1. Global Pharma R&D Outsourcing Market, By Region, 2017-2030 (US$ Bn)
10.5. Musculoskeletal Disorders
10.5.1. Global Pharma R&D Outsourcing Market, By Region, 2017-2030 (US$ Bn)
10.6. Central Nervous System Disorders
10.6.1. Global Pharma R&D Outsourcing Market, By Region, 2017-2030 (US$ Bn)
10.7. Gastrointestinal Disorders
10.7.1. Global Pharma R&D Outsourcing Market, By Region, 2017-2030 (US$ Bn)
10.8. Other Therapy Areas
10.8.1. Global Pharma R&D Outsourcing Market, By Region, 2017-2030 (US$ Bn)

11. Global Pharma R&D Outsourcing Market, By Region
11.1. Global Pharma R&D Outsourcing Market Overview, by Region
11.1.1. Global Pharma R&D Outsourcing Market, By Region, 2022 vs 2030 (in%)
11.2. Product Type
11.2.1. Global Pharma R&D Outsourcing Market, By Product Type, 2017-2030 (US$ Bn)
11.3. Stage of development
11.3.1. Global Pharma R&D Outsourcing Market, By Stage of development, 2017-2030 (US$ Bn)
11.4. Company Size
11.4.1. Global Pharma R&D Outsourcing Market, By Company Size, 2017-2030 (US$ Bn)
11.5. Therapy Area
11.5.1. Global Pharma R&D Outsourcing Market, By Therapy Area, 2017-2030 (US$ Bn)

12. North America Pharma R&D Outsourcing Market Analysis
12.1. North America Pharma R&D Outsourcing Market, By Product Type, 2017-2030(US$ Bn)
12.1.1. Overview
12.1.2. SRC Analysis
12.2. North America Pharma R&D Outsourcing Market, By Stage of development, 2017-2030(US$ Bn)
12.2.1. Overview
12.2.2. SRC Analysis
12.3. North America Pharma R&D Outsourcing Market, By Company Size, 2017-2030(US$ Bn)
12.3.1. Overview
12.3.2. SRC Analysis
12.4. North America Pharma R&D Outsourcing Market, By Therapy Area, 2017-2030(US$ Bn)
12.4.1. Overview
12.4.2. SRC Analysis
12.5. North America Pharma R&D Outsourcing Market, by Country, 2017-2030(US$ Bn)
12.5.1. North America Pharma R&D Outsourcing Market, by Country, 2022 Vs 2030 (in %)
12.5.2. U.S.
12.5.2.1. U.S. Pharma R&D Outsourcing Market Estimates and Forecast, 2017-2030(US$ Bn)
12.5.2.2. U.S. Pharma R&D Outsourcing, By Product Type, 2017-2030(US$ Bn)
12.5.2.3. U.S. Pharma R&D Outsourcing, By Stage of development, 2017-2030(US$ Bn)
12.5.2.4. U.S. Pharma R&D Outsourcing, By Company Size, 2017-2030 (US$ Bn)
12.5.2.5. U.S. Pharma R&D Outsourcing, By Therapy Area, 2017-2030 (US$ Bn)
12.5.3. Canada
12.5.3.1. Canada Pharma R&D Outsourcing Market Estimates and Forecast, 2017-2030(US$ Bn)
12.5.3.2. Canada Pharma R&D Outsourcing, By Product Type, 2017-2030(US$ Bn)
12.5.3.3. Canada Pharma R&D Outsourcing, By Stage of development, 2017-2030(US$ Bn)
12.5.3.4. Canada Pharma R&D Outsourcing, By Company Size, 2017-2030 (US$ Bn)
12.5.3.5. Canada Pharma R&D Outsourcing, By Therapy Area, 2017-2030 (US$ Bn)
12.5.4. Mexico
12.5.4.1. Mexico Pharma R&D Outsourcing Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.5.4.2. Mexico Pharma R&D Outsourcing, By Product Type, 2017-2030 (US$ Bn)
12.5.4.3. Mexico Pharma R&D Outsourcing, By Stage of development, 2017-2030 (US$ Bn)
12.5.4.4. Mexico Pharma R&D Outsourcing, By Company Size, 2017-2030 (US$ Bn)
12.5.4.5. Mexico Pharma R&D Outsourcing, By Therapy Area, 2017-2030 (US$ Bn)

13. Europe Pharma R&D Outsourcing Market Analysis
13.1. Europe Pharma R&D Outsourcing Market, By Product Type, 2017-2030(US$ Bn)
13.1.1. Overview
13.1.2. SRC Analysis
13.2. Europe Pharma R&D Outsourcing Market, By Stage of development, 2017-2030(US$ Bn)
13.2.1. Overview
13.2.2. SRC Analysis
13.3. Europe Pharma R&D Outsourcing Market, By Company Size, 2017-2030(US$ Bn)
13.3.1. Overview
13.3.2. SRC Analysis
13.4. Europe Pharma R&D Outsourcing Market, By Therapy Area, 2017-2030(US$ Bn)
13.4.1. Overview
13.4.2. SRC Analysis
13.5. Europe Pharma R&D Outsourcing Market, by Country, 2017-2030(US$ Bn)
13.5.1. EuropePharma R&D Outsourcing Market, by Country, 2022 Vs 2030 (in%)
13.5.2. Germany
13.5.2.1. Germany Pharma R&D Outsourcing Market Estimates and Forecast, 2017-2030(US$ Bn)
13.5.2.2. Germany Pharma R&D Outsourcing, By Product Type, 2017-2030(US$ Bn)
13.5.2.3. Germany Pharma R&D Outsourcing, By Stage of development, 2017-2030(US$ Bn)
13.5.3. Germany Pharma R&D Outsourcing, By Company Size, 2017-2030 (US$ Bn)
13.5.4. Germany Pharma R&D Outsourcing, By Therapy Area, 2017-2030 (US$ Bn)
13.5.5. France
13.5.5.1. France Pharma R&D Outsourcing Market Estimates and Forecast, 2017-2030(US$ Bn)
13.5.5.2. France Pharma R&D Outsourcing, By Product Type, 2017-2030(US$ Bn)
13.5.5.3. France Pharma R&D Outsourcing, By Stage of development, 2017-2030(US$ Bn)
13.5.5.4. France Pharma R&D Outsourcing, By Company Size, 2017-2030 (US$ Bn)
13.5.5.5. France Pharma R&D Outsourcing, By Therapy Area, 2017-2030 (US$ Bn)
13.5.6. UK
13.5.6.1. UK Pharma R&D Outsourcing Market Estimates and Forecast, 2017-2030(US$ Bn)
13.5.6.2. UK Pharma R&D Outsourcing, By Product Type, 2017-2030(US$ Bn)
13.5.6.3. UK Pharma R&D Outsourcing, By Stage of development, 2017-2030(US$ Bn)
13.5.6.4. UK Pharma R&D Outsourcing, By Company Size, 2017-2030 (US$ Bn)
13.5.6.5. UK Pharma R&D Outsourcing, By Therapy Area, 2017-2030 (US$ Bn)
13.5.7. Italy
13.5.7.1. Italy Pharma R&D Outsourcing Market Estimates and Forecast, 2017-2030(US$ Bn)
13.5.7.2. Italy Pharma R&D Outsourcing, By Product Type, 2017-2030(US$ Bn)
13.5.7.3. Italy Pharma R&D Outsourcing, By Stage of development, 2017-2030(US$ Bn)
13.5.7.4. Italy Pharma R&D Outsourcing, By Company Size, 2017-2030 (US$ Bn)
13.5.7.5. Italy Pharma R&D Outsourcing, By Therapy Area, 2017-2030 (US$ Bn)
13.5.8. Spain
13.5.8.1. Spain Pharma R&D Outsourcing Market Estimates and Forecast, 2017-2030(US$ Bn)
13.5.8.2. Spain Pharma R&D Outsourcing, By Product Type, 2017-2030(US$ Bn)
13.5.8.3. Spain Pharma R&D Outsourcing, By Stage of development, 2017-2030(US$ Bn)
13.5.8.4. Spain Pharma R&D Outsourcing, By Company Size, 2017-2030 (US$ Bn)
13.5.8.5. Spain Pharma R&D Outsourcing, By Therapy Area, 2017-2030 (US$ Bn)
13.5.9. Rest of Europe
13.5.9.1. Rest of Europe Pharma R&D Outsourcing Market Estimates and Forecast, 2017-2030(US$ Bn)
13.5.9.2. Rest of Europe Pharma R&D Outsourcing, By Product Type, 2017-2030(US$ Bn)
13.5.9.3. Rest of Europe Pharma R&D Outsourcing, By Stage of development, 2017-2030(US$ Bn)
13.5.9.4. Rest of Europe Pharma R&D Outsourcing, By Company Size, 2017-2030 (US$ Bn)
13.5.9.5. Rest of Europe Pharma R&D Outsourcing, By Therapy Area, 2017-2030 (US$ Bn)

14. Asia Pacific Pharma R&D Outsourcing Market Analysis
14.1. Asia Pacific Pharma R&D Outsourcing Market, By Product Type, 2017-2030(US$ Bn)
14.1.1. Overview
14.1.2. SRC Analysis
14.2. Asia Pacific Pharma R&D Outsourcing Market, By Stage of development, 2017-2030(US$ Bn)
14.2.1. Overview
14.2.2. SRC Analysis
14.3. Asia Pacific Pharma R&D Outsourcing Market, By Company Size, 2017-2030(US$ Bn)
14.3.1. Overview
14.3.2. SRC Analysis
14.4. Asia Pacific Pharma R&D Outsourcing Market, By Therapy Area, 2017-2030(US$ Bn)
14.4.1. Overview
14.4.2. SRC Analysis
14.5. Asia Pacific Pharma R&D Outsourcing Market, by Country, 2017-2030(US$ Bn)
14.5.1. Asia PacificPharma R&D Outsourcing Market, by Country, 2022 Vs 2030 (in%)
14.5.2. China
14.5.2.1. China Pharma R&D Outsourcing Market Estimates and Forecast, 2017-2030(US$ Bn)
14.5.2.2. China Pharma R&D Outsourcing, By Product Type, 2017-2030(US$ Bn)
14.5.2.3. China Pharma R&D Outsourcing, By Stage of development, 2017-2030(US$ Bn)
14.5.2.4. China Pharma R&D Outsourcing, By Company Size, 2017-2030 (US$ Bn)
14.5.2.5. China Pharma R&D Outsourcing, By Therapy Area, 2017-2030 (US$ Bn)
14.5.3. Japan
14.5.3.1. Japan Pharma R&D Outsourcing Market Estimates and Forecast, 2017-2030(US$ Bn)
14.5.3.2. Japan Pharma R&D Outsourcing, By Product Type, 2017-2030(US$ Bn)
14.5.3.3. Japan Pharma R&D Outsourcing, By Stage of development, 2017-2030(US$ Bn)
14.5.3.4. Japan Pharma R&D Outsourcing, By Company Size, 2017-2030 (US$ Bn)
14.5.3.5. Japan Pharma R&D Outsourcing, By Therapy Area, 2017-2030 (US$ Bn)
14.5.4. India
14.5.4.1. India Pharma R&D Outsourcing Market Estimates and Forecast, 2017-2030(US$ Bn)
14.5.4.2. India Pharma R&D Outsourcing, By Product Type, 2017-2030(US$ Bn)
14.5.4.3. India Pharma R&D Outsourcing, By Stage of development, 2017-2030(US$ Bn)
14.5.4.4. India Pharma R&D Outsourcing, By Company Size, 2017-2030 (US$ Bn)
14.5.4.5. India Pharma R&D Outsourcing, By Therapy Area, 2017-2030 (US$ Bn)
14.5.5. South Korea
14.5.5.1. South Korea Pharma R&D Outsourcing Market Estimates and Forecast, 2017-2030(US$ Bn)
14.5.5.2. South Korea Pharma R&D Outsourcing, By Product Type, 2017-2030(US$ Bn)
14.5.5.3. South Korea Pharma R&D Outsourcing, By Stage of development, 2017-2030(US$ Bn)
14.5.5.4. South Korea Pharma R&D Outsourcing, By Company Size, 2017-2030 (US$ Bn)
14.5.5.5. South Korea Pharma R&D Outsourcing, By Therapy Area, 2017-2030 (US$ Bn)
14.5.6. South-East Asia
14.5.6.1. South-East Asia Pharma R&D Outsourcing Market Estimates and Forecast, 2017-2030(US$ Bn)
14.5.6.2. South-East Asia Pharma R&D Outsourcing, By Product Type, 2017-2030(US$ Bn)
14.5.6.3. South-East Asia Pharma R&D Outsourcing, By Stage of development, 2017-2030(US$ Bn)
14.5.6.4. South-East Asia Pharma R&D Outsourcing, By Company Size, 2017-2030 (US$ Bn)
14.5.6.5. South-East Asia Pharma R&D Outsourcing, By Therapy Area, 2017-2030 (US$ Bn)
14.5.7. Rest of Asia Pacific
14.5.7.1. Rest of Asia Pacific Pharma R&D Outsourcing Market Estimates and Forecast, 2017-2030(US$ Bn)
14.5.7.2. Rest of Asia Pacific Pharma R&D Outsourcing, By Product Type, 2017-2030(US$ Bn)
14.5.7.3. Rest of Asia Pacific Pharma R&D Outsourcing, By Stage of development, 2017-2030(US$ Bn)
14.5.7.4. Rest of Asia Pacific Pharma R&D Outsourcing, By Company Size, 2017-2030 (US$ Bn)
14.5.7.5. Rest of Asia Pacific Pharma R&D Outsourcing, By Therapy Area, 2017-2030 (US$ Bn)

15. Latin America Pharma R&D Outsourcing Market Analysis
15.1. Latin America Pharma R&D Outsourcing Market, By Product Type, 2017-2030(US$ Bn)
15.1.1. Overview
15.1.2. SRC Analysis
15.2. Latin America Pharma R&D Outsourcing Market, By Stage of development, 2017-2030(US$ Bn)
15.2.1. Overview
15.2.2. SRC Analysis
15.3. Latin America Pharma R&D Outsourcing Market, By Company Size, 2017-2030(US$ Bn)
15.3.1. Overview
15.3.2. SRC Analysis
15.4. Latin America Pharma R&D Outsourcing Market, By Therapy Area, 2017-2030(US$ Bn)
15.4.1. Overview
15.4.2. SRC Analysis
15.5. Latin America Pharma R&D Outsourcing Market, by Country, 2017-2030(US$ Bn)
15.5.1. LatinAmerica Pharma R&D Outsourcing Market, by Country, 2022 Vs 2030 (in%)
15.5.2. Brazil
15.5.2.1. Brazil Pharma R&D Outsourcing Market Estimates and Forecast, 2017-2030(US$ Bn)
15.5.2.2. Brazil Pharma R&D Outsourcing, By Product Type, 2017-2030(US$ Bn)
15.5.2.3. Brazil Pharma R&D Outsourcing, By Stage of development, 2017-2030(US$ Bn)
15.5.2.4. Brazil Pharma R&D Outsourcing, By Company Size, 2017-2030 (US$ Bn)
15.5.2.5. Brazil Pharma R&D Outsourcing, By Therapy Area, 2017-2030 (US$ Bn)
15.5.3. Argentina
15.5.3.1. Argentina Pharma R&D Outsourcing Market Estimates and Forecast, 2017-2030(US$ Bn)
15.5.3.2. Argentina Pharma R&D Outsourcing, By Product Type, 2017-2030(US$ Bn)
15.5.3.3. Argentina Pharma R&D Outsourcing, By Stage of development, 2017-2030(US$ Bn)
15.5.3.4. Argentina Pharma R&D Outsourcing, By Company Size, 2017-2030 (US$ Bn)
15.5.3.5. Argentina Pharma R&D Outsourcing, By Therapy Area, 2017-2030 (US$ Bn)
15.5.4. Rest of Latin America
15.5.4.1. Rest of Latin America Pharma R&D Outsourcing Market Estimates and Forecast, 2017-2030(US$ Bn)
15.5.4.2. Rest of Latin America Pharma R&D Outsourcing, By Product Type, 2017-2030(US$ Bn)
15.5.4.3. Rest of Latin America Pharma R&D Outsourcing, By Stage of development, 2017-2030(US$ Bn)
15.5.4.4. Rest of Latin America Pharma R&D Outsourcing, By Company Size, 2017-2030 (US$ Bn)
15.5.4.5. Rest of Latin America Pharma R&D Outsourcing, By Therapy Area, 2017-2030 (US$ Bn)

16. Middle East and Africa Pharma R&D Outsourcing Market Analysis
16.1. Middle East and Africa Pharma R&D Outsourcing Market, By Product Type, 2017-2030(US$ Bn)
16.1.1. Overview
16.1.2. SRC Analysis
16.2. Middle East and Africa Pharma R&D Outsourcing Market, By Stage of development, 2017-2030(US$ Bn)
16.2.1. Overview
16.2.2. SRC Analysis
16.3. Middle East and Africa Pharma R&D Outsourcing Market, By Company Size, 2017-2030(US$ Bn)
16.3.1. Overview
16.3.2. SRC Analysis
16.4. Middle East and Africa Pharma R&D Outsourcing Market, By Therapy Area, 2017-2030(US$ Bn)
16.4.1. Overview
16.4.2. SRC Analysis
16.5. Middle East and Africa Pharma R&D Outsourcing Market, by Country, 2017-2030(US$ Bn)
16.5.1. Middle East and AfricaPharma R&D Outsourcing Market, by Country, 2022 Vs 2030 (in%)
16.5.2. GCC Countries
16.5.2.1. GCC Countries Pharma R&D Outsourcing Market Estimates and Forecast, 2017-2030(US$ Bn)
16.5.2.2. GCC Countries Pharma R&D Outsourcing, By Product Type, 2017-2030(US$ Bn)
16.5.2.3. GCC Countries Pharma R&D Outsourcing, By Stage of development, 2017-2030(US$ Bn)
16.5.2.4. GCC Countries Pharma R&D Outsourcing, By Company Size, 2017-2030 (US$ Bn)
16.5.2.5. GCC Countries Pharma R&D Outsourcing, By Therapy Area, 2017-2030 (US$ Bn)
16.5.3. South Africa
16.5.3.1. South Africa Pharma R&D Outsourcing Market Estimates and Forecast, 2017-2030(US$ Bn)
16.5.3.2. South Africa Pharma R&D Outsourcing, By Product Type, 2017-2030(US$ Bn)
16.5.3.3. South Africa Pharma R&D Outsourcing, By Stage of development, 2017-2030(US$ Bn)
16.5.3.4. South Africa Pharma R&D Outsourcing, By Company Size, 2017-2030 (US$ Bn)
16.5.3.5. South Africa Pharma R&D Outsourcing, By Therapy Area, 2017-2030 (US$ Bn)
16.5.4. Rest of Middle East and Africa
16.5.4.1. Rest of Middle East and Africa Pharma R&D Outsourcing Market Estimates and Forecast, 2017-2030(US$ Bn)
16.5.4.2. Rest of Middle East and Africa Pharma R&D Outsourcing, By Product Type, 2017-2030(US$ Bn)
16.5.4.3. Rest of Middle East and Africa Pharma R&D Outsourcing, By Stage of development, 2017-2030(US$ Bn)
16.5.4.4. Rest of Middle East and Africa Pharma R&D Outsourcing, By Company Size, 2017-2030 (US$ Bn)
16.5.4.5. Rest of Middle East and Africa Pharma R&D Outsourcing, By Therapy Area, 2017-2030 (US$ Bn)

17. Company Profiles
17.1. Charles River Laboratories
17.1.1. Company Overview
17.1.2. Product Types/Services Portfolio
17.1.3. Geographical Presence
17.1.4. Financial Summary
17.1.4.1. Market Revenue and Net Profit (2019-2022)
17.1.4.2. Business Segment Revenue Analysis
17.1.4.3. Geographical Revenue Analysis
17.2. ICON
17.3. IQVIA
17.4. Labcorp Drug Development
17.5. Medpace
17.6. Parexel International Corporation
17.7. Syneos Health
17.8. Thermo Fisher Scientific
17.9. Wuxi AppTec
17.10. Lonza
17.11. Boehringer Ingelheim
17.12. Samsung Biologics
17.13. AbbVie
17.14. Advanced Clinical
17.15. BioAnalytix
17.16. Asymchem
17.17. Alcami
17.18. Bavarian Nordic
17.19. Catalent
17.20. Curia Global
17.21. ChemPartner
17.22. CMED
17.23. Criterium
17.24. Cromos Pharma
17.25. Evotec
17.26. Jubilant HollisterStier
17.27. KBI Biopharma
17.28. KCR S.A.
17.29. Kemwell Biopharma
17.30. Mesned Pharma Consult Center
17.31. Midas Pharma
17.32. Medelis
17.33. Merck KGaA
17.34. OCT Clinical
17.35. Pharmaceutics International
17.36. ProTrials Research
17.37. PROMETRIKA
17.38. QPS
17.39. Singota Solutions
17.40. Sofpromed
17.41. Sanofi
17.42. Taros chemicals
17.43. Veristat
17.44. Worldwide Clinical Trials
17.45. WuXi Biologics
17.46. Wacker Biotech B.V

List of Figures
FIG. 1 Global Pharma R&D Outsourcing Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Pharma R&D Outsourcing Market Segmentation
FIG. 4 Global Pharma R&D Outsourcing Market, By Product Type, 2022(US$ Bn)
FIG. 5 Global Pharma R&D Outsourcing Market, By Stage of development, 2022(US$ Bn)
FIG. 6 Global Pharma R&D Outsourcing Market, By Company Size, 2022 (US$ Bn)
FIG. 7 Global Pharma R&D Outsourcing Market, By Therapy Area, 2022 (US$ Bn)
FIG. 8 Global Pharma R&D Outsourcing Market, by Geography, 2022(US$ Bn)
FIG. 9 Attractive Investment Proposition, By Product Type, 2022
FIG. 10 Attractive Investment Proposition, By Stage of development, 2022
FIG. 11 Attractive Investment Proposition, By Company Size, 2022
FIG. 12 Attractive Investment Proposition, By Therapy Area, 2022
FIG. 13 Attractive Investment Proposition, by Geography, 2022
FIG. 14 Global Market Share Analysis of Key Pharma R&D Outsourcing Market Manufacturers, 2022
FIG. 15 Global Market Positioning of Key Pharma R&D Outsourcing Market Manufacturers, 2022
FIG. 16 Global Pharma R&D Outsourcing Market Value Contribution, By Product Type, 2022&2030 (Value %)
FIG. 17 Global Pharma R&D OutsourcingMarket, by Small Molecules, Value, 2017-2030(US$ Bn)
FIG. 18 Global Pharma R&D OutsourcingMarket, by Biologics, Value, 2017-2030(US$ Bn)
FIG. 19 Global Pharma R&D Outsourcing Market Value Contribution, By Stage of development, 2022&2030 (Value %)
FIG. 20 Global Pharma R&D OutsourcingMarket, by Clinical, Value, 2017-2030(US$ Bn)
FIG. 21 Global Pharma R&D OutsourcingMarket, by Non-Clinical, 2017-2030(US$ Bn)
FIG. 22 Global Pharma R&D Outsourcing Market Value Contribution, By Company Size, 2022 & 2030 (Value %)
FIG. 23 Global Pharma R&D Outsourcing Market, by Small & Mid-Sized Companies, Value, 2017-2030 (US$ Bn)
FIG. 24 Global Pharma R&D Outsourcing Market, by Large Companies, 2017-2030 (US$ Bn)
FIG. 25 Global Pharma R&D Outsourcing Market Value Contribution, By Therapy Area, 2022 & 2030 (Value %)
FIG. 26 Global Pharma R&D Outsourcing Market, by Oncology, Value, 2017-2030 (US$ Bn)
FIG. 27 Global Pharma R&D Outsourcing Market, by Cardiovascular Diseases, Value, 2017-2030 (US$ Bn)
FIG. 28 Global Pharma R&D Outsourcing Market, by Infectious Diseases, Value, 2017-2030 (US$ Bn)
FIG. 29 Global Pharma R&D Outsourcing Market, by Musculoskeletal Disorders, Value, 2017-2030 (US$ Bn)
FIG. 30 Global Pharma R&D Outsourcing Market, by Central Nervous System Disorders, Value, 2017-2030 (US$ Bn)
FIG. 31 Global Pharma R&D Outsourcing Market, by Gastrointestinal Disorders, Value, 2017-2030 (US$ Bn)
FIG. 32 Global Pharma R&D Outsourcing Market, by Other Therapy Areas, Value, 2017-2030 (US$ Bn)
FIG. 33 North America Pharma R&D Outsourcing Market, 2017-2030 (US$ Bn)
FIG. 34 U.S. Pharma R&D Outsourcing Market, 2017-2030(US$ Bn)
FIG. 35 Canada Pharma R&D Outsourcing Market, 2017-2030(US$ Bn)
FIG. 36 Europe Pharma R&D Outsourcing Market, 2017-2030 (US$ Bn)
FIG. 37 Germany Pharma R&D Outsourcing Market, 2017-2030(US$ Bn)
FIG. 38 France Pharma R&D Outsourcing Market, 2017-2030(US$ Bn)
FIG. 39 U.K. Pharma R&D Outsourcing Market, 2017-2030(US$ Bn)
FIG. 40 Italy Pharma R&D Outsourcing Market, 2017-2030(US$ Bn)
FIG. 41 Spain Pharma R&D Outsourcing Market, 2017-2030(US$ Bn)
FIG. 42 Rest of Europe Pharma R&D Outsourcing Market, 2017-2030(US$ Bn)
FIG. 43 Asia Pacific Pharma R&D Outsourcing Market, 2017-2030 (US$ Bn)
FIG. 44 China Pharma R&D Outsourcing Market, 2017-2030(US$ Bn)
FIG. 45 Japan Pharma R&D Outsourcing Market, 2017-2030(US$ Bn)
FIG. 46 India Pharma R&D Outsourcing Market, 2017-2030(US$ Bn)
FIG. 47 South Korea Pharma R&D Outsourcing Market, 2017-2030(US$ Bn)
FIG. 48 South-East Asia Pharma R&D Outsourcing Market, 2017-2030(US$ Bn)
FIG. 49 Rest of Asia Pacific Pharma R&D Outsourcing Market, 2017-2030(US$ Bn)
FIG. 50 Latin America Pharma R&D Outsourcing Market, 2017-2030(US$ Bn)
FIG. 51 Brazil Pharma R&D Outsourcing Market, 2017-2030(US$ Bn)
FIG. 52 Mexico Pharma R&D Outsourcing Market, 2017-2030(US$ Bn)
FIG. 53 Rest of Latin America Pharma R&D Outsourcing Market, 2017-2030(US$ Bn)
FIG. 54 Middle East & Africa Pharma R&D Outsourcing Market, 2017-2030(US$ Bn)
FIG. 55 GCC Countries Pharma R&D Outsourcing Market, 2017-2030(US$ Bn)
FIG. 56 South Africa Pharma R&D Outsourcing Market, 2017-2030(US$ Bn)
FIG. 57 Rest of Middle East and Africa Pharma R&D Outsourcing Market, 2017-2030(US$ Bn)

List of Tables
TABLE 1 Market Snapshot: Global Pharma R&D OutsourcingMarket
TABLE 2 Global Pharma R&D Outsourcing Market: Market Drivers Impact Analysis
TABLE 3 Global Pharma R&D Outsourcing Market: Market Restraints Impact Analysis
TABLE 4 Global Pharma R&D Outsourcing Market, by Competitive Benchmarking,2022
TABLE 5 Global Pharma R&D Outsourcing Market, by Geographical Presence Analysis, 2022
TABLE 6 Global Pharma R&D Outsourcing Market, by Key Strategies Analysis, 2022
TABLE 7 Global Pharma R&D Outsourcing Market, by Small Molecules, By Region, 2017-2022(US$ Bn)
TABLE 8 Global Pharma R&D Outsourcing Market, by Biologics, By Region, 2023-2030(US$ Bn)
TABLE 9 Global Pharma R&D Outsourcing Market, by Clinical, By Region, 2017-2022(US$ Bn)
TABLE 10 Global Pharma R&D Outsourcing Market, by Clinical, By Region, 2023-2030(US$ Bn)
TABLE 11 Global Pharma R&D Outsourcing Market, by Non-Clinical, By Region, 2017-2022(US$ Bn)
TABLE 12 Global Pharma R&D Outsourcing Market, by Non-Clinical, By Region, 2023-2030(US$ Bn)
TABLE 13 Global Pharma R&D Outsourcing Market, by Small & Mid-Sized Companies, By Region, 2017-2022(US$ Bn)
TABLE 14 Global Pharma R&D Outsourcing Market, by Small & Mid-Sized Companies, By Region, 2023-2030(US$ Bn)
TABLE 15 Global Pharma R&D Outsourcing Market, by Large Companies, By Region, 2017-2022(US$ Bn)
TABLE 16 Global Pharma R&D Outsourcing Market, by Large Companies, By Region, 2023-2030(US$ Bn)
TABLE 17 Global Pharma R&D Outsourcing Market, by Oncology, By Region, 2023-2030(US$ Bn)
TABLE 18 Global Pharma R&D Outsourcing Market, by Oncology, By Region, 2023-2030(US$ Bn)
TABLE 19 Global Pharma R&D Outsourcing Market, by Cardiovascular Diseases, By Region, 2023-2030(US$ Bn)
TABLE 20 Global Pharma R&D Outsourcing Market, by Cardiovascular Diseases, By Region, 2023-2030(US$ Bn)
TABLE 21 Global Pharma R&D Outsourcing Market, by Infectious Diseases, By Region, 2023-2030(US$ Bn)
TABLE 22 Global Pharma R&D Outsourcing Market, by Infectious Diseases, By Region, 2023-2030(US$ Bn)
TABLE 23 Global Pharma R&D Outsourcing Market, by Central Nervous System Disorders, By Region, 2023-2030(US$ Bn)
TABLE 24 Global Pharma R&D Outsourcing Market, by Central Nervous System Disorders, By Region, 2023-2030(US$ Bn)
TABLE 25 Global Pharma R&D Outsourcing Market, by Gastrointestinal Disorders, By Region, 2023-2030(US$ Bn)
TABLE 26 Global Pharma R&D Outsourcing Market, by Gastrointestinal Disorders, By Region, 2023-2030(US$ Bn)
TABLE 27 Global Pharma R&D Outsourcing Market, by Other Therapy Areas, By Region, 2023-2030(US$ Bn)
TABLE 28 Global Pharma R&D Outsourcing Market, by Other Therapy Areas, By Region, 2023-2030(US$ Bn)
TABLE 29 Global Pharma R&D Outsourcing Market, By Product Type, 2017-2022(US$ Bn)
TABLE 30 Global Pharma R&D Outsourcing Market, By Product Type, 2023-2030(US$ Bn)
TABLE 31 Global Pharma R&D Outsourcing Market, By Stage of development, 2017-2022(US$ Bn)
TABLE 32 Global Pharma R&D Outsourcing Market, By Stage of development, 2023-2030(US$ Bn)
TABLE 33 Global Pharma R&D Outsourcing Market, By Company Size, 2017-2022(US$ Bn)
TABLE 34 Global Pharma R&D Outsourcing Market, By Company Size, 2023-2030 (US$ Bn)
TABLE 35 Global Pharma R&D Outsourcing Market, By Therapy Area, 2017-2022(US$ Bn)
TABLE 36 Global Pharma R&D Outsourcing Market, By Therapy Area, 2023-2030(US$ Bn)
TABLE 37 Global Pharma R&D Outsourcing Market, by Region, 2017-2022(US$ Bn)
TABLE 38 Global Pharma R&D Outsourcing Market, by Region, 2023-2030(US$ Bn)
TABLE 39 North America Pharma R&D Outsourcing Market, By Product Type, 2017-2022(US$ Bn)
TABLE 40 North America Pharma R&D Outsourcing Market, By Product Type, 2023-2030(US$ Bn)
TABLE 41 North America Pharma R&D Outsourcing Market, By Stage of development, 2017-2022(US$ Bn)
TABLE 42 North America Pharma R&D Outsourcing Market, By Stage of development, 2023-2030(US$ Bn)
TABLE 43 North America Pharma R&D Outsourcing Market, By Company Size, 2017-2022(US$ Bn)
TABLE 44 North America Pharma R&D Outsourcing Market, By Company Size, 2023-2030(US$ Bn)
TABLE 45 North America Pharma R&D Outsourcing Market, By Therapy Area, 2017-2022(US$ Bn)
TABLE 46 North America Pharma R&D Outsourcing Market, By Therapy Area, 2023-2030(US$ Bn)
TABLE 47 North America Pharma R&D Outsourcing Market, by Country, 2017-2022(US$ Bn)
TABLE 48 North America Pharma R&D Outsourcing Market, by Country, 2023-2030(US$ Bn)
TABLE 49 United States Pharma R&D Outsourcing Market, By Product Type, 2017-2022(US$ Bn)
TABLE 50 United States Pharma R&D Outsourcing Market, By Product Type, 2023-2030(US$ Bn)
TABLE 51 United States Pharma R&D Outsourcing Market, By Stage of development, 2017-2022(US$ Bn)
TABLE 52 United States Pharma R&D Outsourcing Market, By Stage of development, 2023-2030(US$ Bn)
TABLE 53 United States Pharma R&D Outsourcing Market, By Company Size, 2017-2022(US$ Bn)
TABLE 54 United States Pharma R&D Outsourcing Market, By Company Size, 2023-2030(US$ Bn)
TABLE 55 United States Pharma R&D Outsourcing Market, By Therapy Area, 2017-2022(US$ Bn)
TABLE 56 United States Pharma R&D Outsourcing Market, By Therapy Area, 2023-2030(US$ Bn)
TABLE 57 Canada Pharma R&D Outsourcing Market, By Product Type, 2017-2022(US$ Bn)
TABLE 58 Canada Pharma R&D Outsourcing Market, By Product Type, 2023-2030(US$ Bn)
TABLE 59 Canada Pharma R&D Outsourcing Market, by Stage of developments, 2017-2022(US$ Bn)
TABLE 60 Canada Pharma R&D Outsourcing Market, by Stage of development, 2023-2030(US$ Bn)
TABLE 61 Canada Pharma R&D Outsourcing Market, By Company Size, 2017-2022(US$ Bn)
TABLE 62 Canada Pharma R&D Outsourcing Market, By Company Size, 2023-2030(US$ Bn)
TABLE 63 Canada Pharma R&D Outsourcing Market, By Therapy Area, 2017-2022(US$ Bn)
TABLE 64 Canada Pharma R&D Outsourcing Market, By Therapy Area, 2023-2030(US$ Bn)
TABLE 65 Mexico Pharma R&D Outsourcing Market, By Product Type, 2017-2022(US$ Bn)
TABLE 66 Mexico Pharma R&D Outsourcing Market, By Product Type, 2023-2030(US$ Bn)
TABLE 67 Mexico Pharma R&D Outsourcing Market, by Stage of development, 2017-2022(US$ Bn)
TABLE 68 Mexico Pharma R&D Outsourcing Market, by Stage of development, 2023-2030(US$ Bn)
TABLE 69 Mexico Pharma R&D Outsourcing Market, By Company Size, 2017-2022(US$ Bn)
TABLE 70 Mexico Pharma R&D Outsourcing Market, By Company Size, 2023-2030(US$ Bn)
TABLE 71 Mexico Pharma R&D Outsourcing Market, By Therapy Area, 2017-2022(US$ Bn)
TABLE 72 Mexico Pharma R&D Outsourcing Market, By Therapy Area, 2023-2030(US$ Bn)
TABLE 73 Europe Pharma R&D Outsourcing Market, By Product Type, 2017-2022(US$ Bn)
TABLE 74 Europe Pharma R&D Outsourcing Market, By Product Type, 2023-2030(US$ Bn)
TABLE 75 Europe Pharma R&D Outsourcing Market, by Stage of development, 2017-2022(US$ Bn)
TABLE 76 Europe Pharma R&D Outsourcing Market, by Stage of development, 2023-2030(US$ Bn)
TABLE 77 Europe Pharma R&D Outsourcing Market, By Company Size, 2017-2022(US$ Bn)
TABLE 78 Europe Pharma R&D Outsourcing Market, By Company Size, 2023-2030(US$ Bn)
TABLE 79 Europe Pharma R&D Outsourcing Market, by Therapy Area, 2017-2022(US$ Bn)
TABLE 80 Europe Pharma R&D Outsourcing Market, by Therapy Area, 2023-2030(US$ Bn)
TABLE 81 Germany Pharma R&D Outsourcing Market, By Product Type, 2017-2022(US$ Bn)
TABLE 82 Germany Pharma R&D Outsourcing Market, By Product Type, 2023-2030(US$ Bn)
TABLE 83 Germany Pharma R&D Outsourcing Market, by Stage of development, 2017-2022(US$ Bn)
TABLE 84 Germany Pharma R&D Outsourcing Market, by Stage of development, 2023-2030(US$ Bn)
TABLE 85 Germany Pharma R&D Outsourcing Market, By Company Size, 2017-2022(US$ Bn)
TABLE 86 Germany Pharma R&D Outsourcing Market, By Company Size, 2023-2030(US$ Bn)
TABLE 87 Germany Pharma R&D Outsourcing Market, By Therapy Area, 2017-2022(US$ Bn)
TABLE 88 Germany Pharma R&D Outsourcing Market, By Therapy Area, 2023-2030(US$ Bn)
TABLE 89 France Pharma R&D Outsourcing Market, By Product Type, 2017-2022(US$ Bn)
TABLE 90 France Pharma R&D Outsourcing Market, By Product Type, 2023-2030(US$ Bn)
TABLE 91 France Pharma R&D Outsourcing Market, by Stage of development, 2017-2022(US$ Bn)
TABLE 92 France Pharma R&D Outsourcing Market, by Stage of development, 2023-2030(US$ Bn)
TABLE 93 France Pharma R&D Outsourcing Market, By Company Size, 2017-2022(US$ Bn)
TABLE 94 France Pharma R&D Outsourcing Market, By Company Size, 2023-2030(US$ Bn)
TABLE 95 France Pharma R&D Outsourcing Market, By Therapy Area, 2017-2022(US$ Bn)
TABLE 96 France Pharma R&D Outsourcing Market, By Therapy Area, 2023-2030(US$ Bn)
TABLE 97 United Kingdom Pharma R&D Outsourcing Market, By Product Type, 2017-2022(US$ Bn)
TABLE 98 United Kingdom Pharma R&D Outsourcing Market, By Product Type, 2023-2030(US$ Bn)
TABLE 99 United Kingdom Pharma R&D Outsourcing Market, by Stage of development, 2017-2022(US$ Bn)
TABLE 100 United Kingdom Pharma R&D Outsourcing Market, by Stage of development, 2023-2030(US$ Bn)
TABLE 101 United Kingdom Pharma R&D Outsourcing Market, By Company Size, 2017-2022(US$ Bn)
TABLE 102 United Kingdom Pharma R&D Outsourcing Market, By Company Size, 2023-2030(US$ Bn)
TABLE 103 United Kingdom Pharma R&D Outsourcing Market, By Therapy Area, 2017-2022(US$ Bn)
TABLE 104 United Kingdom Pharma R&D Outsourcing Market, By Therapy Area, 2023-2030(US$ Bn)
TABLE 105 Italy Pharma R&D Outsourcing Market, By Product Type, 2017-2022(US$ Bn)
TABLE 106 Italy Pharma R&D Outsourcing Market, By Product Type, 2023-2030(US$ Bn)
TABLE 107 Italy Pharma R&D Outsourcing Market, by Stage of development, 2017-2022(US$ Bn)
TABLE 108 Italy Pharma R&D Outsourcing Market, by Stage of development, 2023-2030(US$ Bn)
TABLE 109 Italy Pharma R&D Outsourcing Market, By Company Size, 2017-2022(US$ Bn)
TABLE 110 Italy Pharma R&D Outsourcing Market, By Company Size, 2023-2030(US$ Bn)
TABLE 111 Italy Pharma R&D Outsourcing Market, By Therapy Area, 2017-2022(US$ Bn)
TABLE 112 Italy Pharma R&D Outsourcing Market, By Therapy Area, 2023-2030(US$ Bn)
TABLE 113 Spain Pharma R&D Outsourcing Market, By Product Type, 2017-2022(US$ Bn)
TABLE 114 Spain Pharma R&D Outsourcing Market, By Product Type, 2023-2030(US$ Bn)
TABLE 115 Spain Pharma R&D Outsourcing Market, by Stage of development, 2017-2022(US$ Bn)
TABLE 116 Spain Pharma R&D Outsourcing Market, by Stage of development, 2023-2030(US$ Bn)
TABLE 117 Spain Pharma R&D Outsourcing Market, By Company Size, 2017-2022(US$ Bn)
TABLE 118 Spain Pharma R&D Outsourcing Market, By Company Size, 2023-2030(US$ Bn)
TABLE 119 Spain Pharma R&D Outsourcing Market, By Therapy Area, 2017-2022(US$ Bn)
TABLE 120 Spain Pharma R&D Outsourcing Market, By Therapy Area, 2023-2030(US$ Bn)
TABLE 121 Rest of Europe Pharma R&D Outsourcing Market, By Product Type, 2017-2022(US$ Bn)
TABLE 122 Rest of Europe Pharma R&D Outsourcing Market, By Product Type, 2023-2030(US$ Bn)
TABLE 123 Rest of Europe Pharma R&D Outsourcing Market, by Stage of development, 2017-2022(US$ Bn)
TABLE 124 Rest of Europe Pharma R&D Outsourcing Market, by Stage of development, 2023-2030(US$ Bn)
TABLE 125 Rest of Europe Pharma R&D Outsourcing Market, By Company Size, 2017-2022(US$ Bn)
TABLE 126 Rest of Europe Pharma R&D Outsourcing Market, By Company Size, 2023-2030(US$ Bn)
TABLE 127 Rest of Europe Pharma R&D Outsourcing Market, By Therapy Area, 2017-2022(US$ Bn)
TABLE 128 Rest of Europe Pharma R&D Outsourcing Market, By Therapy Area, 2023-2030(US$ Bn)
TABLE 129
TABLE 130 Asia Pacific Pharma R&D Outsourcing Market, By Product Type, 2017-2022(US$ Bn)
TABLE 131 Asia Pacific Pharma R&D Outsourcing Market, By Product Type, 2023-2030(US$ Bn)
TABLE 132 Asia Pacific Pharma R&D Outsourcing Market, by Stage of development, 2017-2022(US$ Bn)
TABLE 133 Asia Pacific Pharma R&D Outsourcing Market, by Stage of development, 2023-2030(US$ Bn)
TABLE 134 Asia Pacific Pharma R&D Outsourcing Market, By Company Size, 2017-2022(US$ Bn)
TABLE 135 Asia Pacific Pharma R&D Outsourcing Market, By Company Size, 2023-2030(US$ Bn)
TABLE 136 Asia Pacific Pharma R&D Outsourcing Market, By Therapy Area, 2017-2022(US$ Bn)
TABLE 137 Asia Pacific Pharma R&D Outsourcing Market, By Therapy Area, 2023-2030(US$ Bn)
TABLE 138 China Pharma R&D Outsourcing Market, By Product Type, 2017-2022(US$ Bn)
TABLE 139 China Pharma R&D Outsourcing Market, By Product Type, 2023-2030(US$ Bn)
TABLE 140 China Pharma R&D Outsourcing Market, by Stage of development, 2017-2022(US$ Bn)
TABLE 141 China Pharma R&D Outsourcing Market, by Stage of development, 2023-2030(US$ Bn)
TABLE 142 China Pharma R&D Outsourcing Market, By Company Size, 2017-2022(US$ Bn)
TABLE 143 China Pharma R&D Outsourcing Market, By Company Size, 2023-2030(US$ Bn)
TABLE 144 China Pharma R&D Outsourcing Market, By Therapy Area, 2017-2022(US$ Bn)
TABLE 145 China Pharma R&D Outsourcing Market, By Therapy Area, 2023-2030(US$ Bn)
TABLE 146 Japan Pharma R&D Outsourcing Market, By Product Type, 2017-2022(US$ Bn)
TABLE 147 Japan Pharma R&D Outsourcing Market, By Product Type, 2023-2030(US$ Bn)
TABLE 148 Japan Pharma R&D Outsourcing Market, by Stage of development, 2017-2022(US$ Bn)
TABLE 149 Japan Pharma R&D Outsourcing Market, by Stage of development, 2023-2030(US$ Bn)
TABLE 150 Japan Pharma R&D Outsourcing Market, By Company Size, 2017-2022(US$ Bn)
TABLE 151 Japan Pharma R&D Outsourcing Market, By Company Size, 2023-2030(US$ Bn)
TABLE 152 Japan Pharma R&D Outsourcing Market, By Therapy Area, 2017-2022(US$ Bn)
TABLE 153 Japan Pharma R&D Outsourcing Market, By Therapy Area, 2023-2030(US$ Bn)
TABLE 154 India Pharma R&D Outsourcing Market, By Product Type, 2017-2022(US$ Bn)
TABLE 155 India Pharma R&D Outsourcing Market, By Product Type, 2023-2030(US$ Bn)
TABLE 156 India Pharma R&D Outsourcing Market, by Stage of development, 2017-2022(US$ Bn)
TABLE 157 India Pharma R&D Outsourcing Market, by Stage of development, 2023-2030(US$ Bn)
TABLE 158 India Pharma R&D Outsourcing Market, By Company Size, 2017-2022(US$ Bn)
TABLE 159 India Pharma R&D Outsourcing Market, By Company Size, 2023-2030(US$ Bn)
TABLE 160 India Pharma R&D Outsourcing Market, By Therapy Area, 2017-2022(US$ Bn)
TABLE 161 India Pharma R&D Outsourcing Market, By Therapy Area, 2023-2030(US$ Bn)
TABLE 162 South Korea Pharma R&D Outsourcing Market, By Product Type, 2017-2022(US$ Bn)
TABLE 163 South Korea Pharma R&D Outsourcing Market, By Product Type, 2023-2030(US$ Bn)
TABLE 164 South Korea Pharma R&D Outsourcing Market, by Stage of development, 2017-2022(US$ Bn)
TABLE 165 South Korea Pharma R&D Outsourcing Market, by Stage of development, 2023-2030(US$ Bn)
TABLE 166 South Korea Pharma R&D Outsourcing Market, By Company Size, 2017-2022(US$ Bn)
TABLE 167 South Korea Pharma R&D Outsourcing Market, By Company Size, 2023-2030(US$ Bn)
TABLE 168 South Korea Pharma R&D Outsourcing Market, By Therapy Area, 2017-2022(US$ Bn)
TABLE 169 South Korea Pharma R&D Outsourcing Market, By Therapy Area, 2023-2030(US$ Bn)
TABLE 170 South-East Asia Pharma R&D Outsourcing Market, By Product Type, 2017-2022(US$ Bn)
TABLE 171 South-East Asia Pharma R&D Outsourcing Market, By Product Type, 2023-2030(US$ Bn)
TABLE 172 South-East Asia Pharma R&D Outsourcing Market, by Stage of development, 2017-2022(US$ Bn)
TABLE 173 South-East Asia Pharma R&D Outsourcing Market, by Stage of development, 2023-2030(US$ Bn)
TABLE 174 South-East Asia Pharma R&D Outsourcing Market, By Company Size, 2017-2022(US$ Bn)
TABLE 175 South-East Asia Pharma R&D Outsourcing Market, By Company Size, 2023-2030(US$ Bn)
TABLE 176 South-East Asia Pharma R&D Outsourcing Market, By Therapy Area, 2017-2022(US$ Bn)
TABLE 177 South-East Asia Pharma R&D Outsourcing Market, By Therapy Area, 2023-2030(US$ Bn)
TABLE 178 Rest of Asia Pacific Pharma R&D Outsourcing Market, By Product Type, 2017-2022(US$ Bn)
TABLE 179 Rest of Asia Pacific Pharma R&D Outsourcing Market, By Product Type, 2023-2030(US$ Bn)
TABLE 180 Rest of Asia Pacific Pharma R&D Outsourcing Market, by Stage of development, 2017-2022(US$ Bn)
TABLE 181 Rest of Asia Pacific Pharma R&D Outsourcing Market, by Stage of development, 2023-2030(US$ Bn)
TABLE 182 Rest of Asia Pacific Pharma R&D Outsourcing Market, By Company Size, 2017-2022(US$ Bn)
TABLE 183 Rest of Asia Pacific Pharma R&D Outsourcing Market, By Company Size, 2023-2030(US$ Bn)
TABLE 184 Rest of Asia Pacific Pharma R&D Outsourcing Market, By Therapy Area, 2017-2022(US$ Bn)
TABLE 185 Rest of Asia Pacific Pharma R&D Outsourcing Market, By Therapy Area, 2023-2030(US$ Bn)
TABLE 186 Latin America Pharma R&D Outsourcing Market, By Product Type, 2017-2022(US$ Bn)
TABLE 187 Latin America Pharma R&D Outsourcing Market, By Product Type, 2023-2030(US$ Bn)
TABLE 188 Latin America Pharma R&D Outsourcing Market, by Stage of development, 2017-2022(US$ Bn)
TABLE 189 Latin America Pharma R&D Outsourcing Market, by Stage of development, 2023-2030(US$ Bn)
TABLE 190 Latin America Pharma R&D Outsourcing Market, By Company Size, 2017-2022(US$ Bn)
TABLE 191 Latin America Pharma R&D Outsourcing Market, By Company Size, 2023-2030(US$ Bn)
TABLE 192 Latin America Pharma R&D Outsourcing Market, By Therapy Area, 2017-2022(US$ Bn)
TABLE 193 Latin America Pharma R&D Outsourcing Market, By Therapy Area, 2023-2030(US$ Bn)
TABLE 194 Brazil Pharma R&D Outsourcing Market, By Product Type, 2017-2022(US$ Bn)
TABLE 195 Brazil Pharma R&D Outsourcing Market, By Product Type, 2023-2030(US$ Bn)
TABLE 196 Brazil Pharma R&D Outsourcing Market, by Stage of development, 2017-2022(US$ Bn)
TABLE 197 Brazil Pharma R&D Outsourcing Market, by Stage of development, 2023-2030(US$ Bn)
TABLE 198 Brazil Pharma R&D Outsourcing Market, By Company Size, 2017-2022(US$ Bn)
TABLE 199 Brazil Pharma R&D Outsourcing Market, By Company Size, 2023-2030(US$ Bn)
TABLE 200 Brazil Pharma R&D Outsourcing Market, By Therapy Area, 2017-2022(US$ Bn)
TABLE 201 Brazil Pharma R&D Outsourcing Market, By Therapy Area, 2023-2030(US$ Bn)
TABLE 202 Argentina Pharma R&D Outsourcing Market, By Product Type, 2017-2022(US$ Bn)
TABLE 203 Argentina Pharma R&D Outsourcing Market, By Product Type, 2023-2030(US$ Bn)
TABLE 204 Argentina Pharma R&D Outsourcing Market, by Stage of development, 2017-2022(US$ Bn)
TABLE 205 Argentina Pharma R&D Outsourcing Market, by Stage of development, 2023-2030(US$ Bn)
TABLE 206 Argentina Pharma R&D Outsourcing Market, By Company Size, 2017-2022(US$ Bn)
TABLE 207 Argentina Pharma R&D Outsourcing Market, By Company Size, 2023-2030(US$ Bn)
TABLE 208 Argentina Pharma R&D Outsourcing Market, By Therapy Area, 2017-2022(US$ Bn)
TABLE 209 Argentina Pharma R&D Outsourcing Market, By Therapy Area, 2023-2030(US$ Bn)
TABLE 210 Rest of Latin America Pharma R&D Outsourcing Market, By Product Type, 2017-2022(US$ Bn)
TABLE 211 Rest of Latin America Pharma R&D Outsourcing Market, By Product Type, 2023-2030(US$ Bn)
TABLE 212 Rest of Latin America Pharma R&D Outsourcing Market, by Stage of development, 2017-2022(US$ Bn)
TABLE 213 Rest of Latin America Pharma R&D Outsourcing Market, by Stage of development, 2023-2030(US$ Bn)
TABLE 214 Rest of Latin America Pharma R&D Outsourcing Market, By Company Size, 2017-2022(US$ Bn)
TABLE 215 Rest of Latin America Pharma R&D Outsourcing Market, By Company Size, 2023-2030(US$ Bn)
TABLE 216 Rest of Latin America Pharma R&D Outsourcing Market, By Therapy Area, 2017-2022(US$ Bn)
TABLE 217 Rest of Latin America Pharma R&D Outsourcing Market, By Therapy Area, 2023-2030(US$ Bn)
TABLE 218 Middle East and Africa Pharma R&D Outsourcing Market, By Product Type, 2017-2022(US$ Bn)
TABLE 219 Middle East and Africa Pharma R&D Outsourcing Market, By Product Type, 2023-2030(US$ Bn)
TABLE 220 Middle East and Africa Pharma R&D Outsourcing Market, by Stage of development, 2017-2022(US$ Bn)
TABLE 221 Middle East and Africa Pharma R&D Outsourcing Market, by Stage of development, 2023-2030(US$ Bn)
TABLE 222 Middle East and Africa Pharma R&D Outsourcing Market, By Company Size, 2017-2022(US$ Bn)
TABLE 223 Middle East and Africa Pharma R&D Outsourcing Market, By Company Size, 2023-2030(US$ Bn)
TABLE 224 Middle East and Africa Pharma R&D Outsourcing Market, By Therapy Area, 2017-2022(US$ Bn)
TABLE 225 Middle East and Africa Pharma R&D Outsourcing Market, By Therapy Area, 2023-2030(US$ Bn)
TABLE 226 GCC Countries Pharma R&D Outsourcing Market, By Product Type, 2017-2022(US$ Bn)
TABLE 227 GCC Countries Pharma R&D Outsourcing Market, By Product Type, 2023-2030(US$ Bn)
TABLE 228 GCC Countries Pharma R&D Outsourcing Market, by Stage of development, 2017-2022(US$ Bn)
TABLE 229 GCC Countries Pharma R&D Outsourcing Market, by Stage of development, 2023-2030(US$ Bn)
TABLE 230 GCC Countries Pharma R&D Outsourcing Market, By Company Size, 2017-2022(US$ Bn)
TABLE 231 GCC Countries Pharma R&D Outsourcing Market, By Company Size, 2023-2030(US$ Bn)
TABLE 232 GCC Countries Pharma R&D Outsourcing Market, By Therapy Area, 2017-2022(US$ Bn)
TABLE 233 GCC Countries Pharma R&D Outsourcing Market, By Therapy Area, 2023-2030(US$ Bn)
TABLE 234 South Africa Pharma R&D Outsourcing Market, By Product Type, 2017-2022(US$ Bn)
TABLE 235 South Africa Pharma R&D Outsourcing Market, By Product Type, 2023-2030(US$ Bn)
TABLE 236 South Africa Pharma R&D Outsourcing Market, by Stage of development, 2017-2022(US$ Bn)
TABLE 237 South Africa Pharma R&D Outsourcing Market, by Stage of development, 2023-2030(US$ Bn)
TABLE 238 South Africa Pharma R&D Outsourcing Market, By Company Size, 2017-2022(US$ Bn)
TABLE 239 South Africa Pharma R&D Outsourcing Market, By Company Size, 2023-2030(US$ Bn)
TABLE 240 South Africa Pharma R&D Outsourcing Market, By Therapy Area, 2017-2022(US$ Bn)
TABLE 241 South Africa Pharma R&D Outsourcing Market, By Therapy Area, 2023-2030(US$ Bn)
TABLE 242 Rest of Middle East and Africa Pharma R&D Outsourcing Market, By Product Type, 2017-2022(US$ Bn)
TABLE 243 Rest of Middle East and Africa Pharma R&D Outsourcing Market, By Product Type, 2023-2030(US$ Bn)
TABLE 244 Rest of Middle East and Africa Pharma R&D Outsourcing Market, by Stage of development, 2017-2022(US$ Bn)
TABLE 245 Rest of Middle East and Africa Pharma R&D Outsourcing Market, by Stage of development, 2023-2030(US$ Bn)
TABLE 246 Rest of Middle East and Africa Pharma R&D Outsourcing Market, By Company Size, 2017-2022(US$ Bn)
TABLE 247 Rest of Middle East and Africa Pharma R&D Outsourcing Market, By Company Size, 2023-2030(US$ Bn)
TABLE 248 Rest of Middle East and Africa Pharma R&D Outsourcing Market, By Therapy Area, 2017-2022(US$ Bn)
TABLE 249 Rest of Middle East and Africa Pharma R&D Outsourcing Market, By Therapy Area, 2023-2030(US$ Bn)